Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Melissa Claar, MA, RN, CPNP
Patient Support Professional Nurse Practitioner
Masonic Children's Hospital
University of Minnesota
2450 Riverside Ave
Minneapolis, Minnesota, United States
Nurse Practitioner Melissa Claar, MA, RN, CPNP, helps lead the pediatric sickle cell disease treatment program at University of Minnesota Masonic Children’s Hospital. Claar believes empowerment and education are crucial components of patient care. Claar, a care provider serving the pediatric sickle cell disease program at University of Minnesota Masonic Children’s Hospital, not only guides families through the difficult time, but engages them and encourages them to dive deep into education on sickle cell disease, so they can become partners in the care.
This approach and Claar’s willingness to be a tremendous resource for families has helped the sickle cell disease program expand. Her desire to make a difference was the driving force for her interest in healthcare. Claar’s passion has always been in helping others. Providing excellent comprehensive and compassionate care allows her to make something that is exceptionally difficult for patients and families a little easier.
+myBinderRelated Content
-
Paulette E. Forbes, MPH, MS, APNMs. Paulette E. Forbes serves as an inpa...
-
Howard Woolley, MASHoward Woolley is a philanthropist with ...
-
Data Brief: Healthcare Utilization for Vaso-Occlusive Episodes by People with Sickle Cell Disease in California and ...Many people with sickle cell disease (SC...
-
NewYork-Presbyterian Brooklyn Methodist HospitalThe Sickle Cell/Thalassemia Program at N...
-
Opioid Abuse Backlash Could Hurt Sickle Cell Patients’ Medication Needs, Some FearWith drug overdoses now the leading caus...
-
The Comprehensive Sickle Cell Center at Children’s Hospital of PhiladelphiaThe Comprehensive Sickle Cell Center at ...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
